Original articleEffect on Intraocular Pressure in Patients Receiving Unilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections
Section snippets
Methods
Institutional review board approval was obtained for this Health Insurance Portability and Accountability Act-compliant, retrospective cohort study, and all research adhered to the tenets of the Declaration of Helsinki. We retrospectively reviewed the charts of a consecutive series of 207 neovascular AMD patients who were seen between February 1, 2010 and July 31, 2010, by a single physician (K.B.F.) at 2 offices of the Vitreous Retina Macula Consultants of New York, who were followed for ≥9
Results
A total of 207 patients were included in this study. The mean patient age at the initiation of treatment was 79 years; 35% were male, and 56% of eyes were phakic at the time of initial ranibizumab or bevacizumab injection (see Table 1 for other baseline demographic information). Mean number of total injections was 20.8 (range, 3–48). Mean follow-up time was 148.6 weeks (range, 9.7–274). On ≥2 consecutive visits, 11.6% of treated versus 5.3% of untreated/control eyes experienced IOP elevation of
Discussion
Elevations of IOP were not noted to be a complication of ranibizumab injections in the ANCHOR and MARINA trials as determined by mean monthly preinjection measurements during the 2-year follow-up.1, 2 In the VISION trial,7, 8 there was no evidence of increased mean preinjection IOP over 2 years after the injection of intravitreal pegaptanib every 6 weeks. Mean values for IOP returned to preinjection levels by 1 week after injections. In contrast, post hoc analysis of data from the ANCHOR and
References (21)
- et al.
Short-term intraocular pressure changes after intravitreal injection of bevacizumab
Can J Ophthalmol
(2007) - et al.
Ranibizumab for neovascular age-related macular degeneration
N Engl J Med
(2006) - et al.
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
N Engl J Med
(2006) - et al.
Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents
Am J Ophthalmol
(2008) - et al.
Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration [letter]
Br J Ophthalmol
(2008) - et al.
Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab
Eye (Lond)
(2009) - et al.
Pegaptanib for neovascular age-related macular degeneration
N Engl J Med
(2004) Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials
Ophthalmology
(2006)- et al.
Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents
Br J Ophthalmol
(2011) - et al.
Persistent ocular hypertension following intravitreal ranibizumab
Graefes Arch Clin Exp Ophthalmol
(2008)
Cited by (0)
Manuscript no. 2011-261.
Financial Disclosure(s): The authors have made the following disclosures:
K. Bailey Freund – Consultant, Research Support – Genentech; Consultant– Alcon; Consultant – Regeneron; Consultant – Alimera.
Supported by the LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat Institute, and The Macula Foundation Inc. The funding organizations had no role in the design or conduct of this research.